NCT07908381Phase 2, phase 3Recruiting

A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease

Study sponsor: Enanta Pharmaceuticals, Inc · ENTA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-07Estimated
Enrollment · participants860Estimated
Source updated2026-11-02Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.